Eli Lilly’s LLY0.57%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...

Eli Lilly’s LLY0.66%increase; green up pointing triangle Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration’s approval earlier this month, the company ...

Eli Lilly has published a video about how medicines affect lives to mark its 150th anniversary and the arrival of college basketball stars in its home city. Indianapolis-based Lilly will celebrate 150 ...

Eli Lilly & Co.’s Zepbound is helping to solve one of the most intractable health challenges of our time: obesity. Now, the drugmaker is taking on another significant public health predicament: sleep ...

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug. By Rebecca Robbins Eli Lilly reached a deal on Tuesday to buy Centessa ...

Retatrutide, an experimental diabetes drug produced by Eli Lilly, helped some trial participants lose over 15% of their body weight, according to results of a new study released by the drug ...

Eli Lilly (LLY) shares slipped in the premarket on Tuesday after HSBC downgraded the weight loss drugmaker to Reduce from Hold, issuing the pharma giant’s only sell-equivalent rating on Wall Street, ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. That's good news, but investors are well ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Rising prescription drug costs are top of mind for employers, and GLP-1s are partly responsible. The drugs — while proven highly effective — come at a hefty price tag, leading to many employers having ...

Eli Lilly has officially launched Employer Connect, its direct-to-employer platform for its obesity medications, after teasing the rollout late last year. The drugmaker said in an announcement that ...

Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up. According to lead investigator Dr. Julio Rosenstock, Lilly’s pill ...